Nebula Research & Development LLC Makes New $368,000 Investment in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Nebula Research & Development LLC purchased a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 46,512 shares of the company's stock, valued at approximately $368,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. acquired a new position in Amneal Pharmaceuticals during the fourth quarter worth $81,000. Straightline Group LLC acquired a new position in shares of Amneal Pharmaceuticals during the 4th quarter worth about $92,000. Cibc World Markets Corp bought a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at about $118,000. Janney Montgomery Scott LLC bought a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at about $121,000. Finally, Fox Run Management L.L.C. lifted its stake in Amneal Pharmaceuticals by 69.0% in the 4th quarter. Fox Run Management L.L.C. now owns 20,435 shares of the company's stock valued at $162,000 after purchasing an additional 8,342 shares during the last quarter. Institutional investors own 31.82% of the company's stock.

Analysts Set New Price Targets

Several analysts have issued reports on AMRX shares. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their price objective for the company from $9.00 to $12.00 in a research note on Monday, February 24th. StockNews.com upgraded Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Monday. Finally, Barclays lifted their price objective on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research report on Monday, March 3rd. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $10.80.

Insider Activity

In other news, Director Gautam Patel sold 80,000 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.90, for a total value of $712,000.00. Following the sale, the director now directly owns 1,808,886 shares in the company, valued at approximately $16,099,085.40. This trade represents a 4.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the sale, the insider now directly owns 48,578,209 shares in the company, valued at $405,628,045.15. This trade represents a 9.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 26.56% of the company's stock.

Amneal Pharmaceuticals Stock Down 0.2 %

Shares of Amneal Pharmaceuticals stock traded down $0.01 on Tuesday, hitting $7.53. The stock had a trading volume of 281,784 shares, compared to its average volume of 1,415,541. Amneal Pharmaceuticals, Inc. has a twelve month low of $6.29 and a twelve month high of $9.48. The stock has a market cap of $2.33 billion, a price-to-earnings ratio of -11.11 and a beta of 1.17. The business's 50 day moving average is $8.01 and its two-hundred day moving average is $8.15.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings results on Friday, May 2nd. The company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The business had revenue of $695.42 million during the quarter, compared to analysts' expectations of $714.78 million. As a group, equities analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.